You are here

Article Text

Article menu
Download PDFPDF
Oncology
Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid
  1. Justin Schutte1,
  2. Mahta Mardani1,
  3. Katherine Weilbaecher1,
  4. Vikas Prasad2,
  5. John S A Chrisinger3 and
  6. Nikolaos A Trikalinos4
  1. 1Internal Medicine – Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA
  2. 2Radiology – Nuclear Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA
  3. 3Pathology – Anatomic and Molecular Pathology (AMP), Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA
  4. 4Washington University in St Louis School of Medicine, St Louis, Missouri, USA
  1. Correspondence to Mr Justin Schutte; justins{at}wustl.edu

Abstract

A patient with a long history of bone predominant, metastatic paraganglioma who had multiple episodes of progressive disease despite prior treatments demonstrated a remarkable disease response to zoledronic acid. After 1 year of treatment, there was a complete resolution of lymphadenopathy and disappearance of all somatostatin receptor avid lesions by positron emission tomography-CT and radiopharmaceutical Gallium Ga 68 Dotatate. Stability of disease was further demonstrated by CT over several years. The patient continues on surveillance.

  • Oncology
  • Therapeutic indications
  • Cancer intervention
  • Cancer - see Oncology
  • Calcium and bone

https://doi.org/10.1136/bcr-2024-262628

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: JS, NAT, MM, KW, VP and JSAC. Guarantor is JS.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.